The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Practice patterns in the use of adjuvant therapy for post-menopausal early-stage breast cancer in the pre- and post-Oncotype DX era.
Asma Latif
No relevant relationships to disclose
Alexander C. Small
No relevant relationships to disclose
Erin L. Moshier
No relevant relationships to disclose
Kerin B. Adelson
Honoraria - Genomic Health
George Raptis
No relevant relationships to disclose
James H. Godbold
No relevant relationships to disclose
William K. Oh
No relevant relationships to disclose
Matt D. Galsky
No relevant relationships to disclose